Ascendis Pharma A/S vs Twist Bioscience Corp — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Ascendis Pharma A/S is far larger — about 2.2× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | TWST | |
|---|---|---|
Market Cap | $16.67B | $7.72B |
Sector | Health | Health |
52-Week High | $277.18 | $124.88 |
52-Week Low | $189.74 | $24.16 |
Enterprise Value | $17.04B | $7.65B |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →